Results 21 to 30 of about 305,738 (309)

ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress

Computational and Structural Biotechnology Journal, 2018
We discuss the current status of liquid biopsy and its advantages and challenges with a focus on pre-analytical sample handling, technologies and workflows. The potential of circulating tumor cells and circulating tumor DNA is pointed out and an overview
Martin H.D. Neumann, Sebastian Bender, Thomas Krahn, Thomas Schlange   +3 more
doaj   +1 more source

Clinical correlates of circulating cell-free DNA tumor fraction.

PLoS ONE, 2021
BackgroundOncology applications of cell-free DNA analysis are often limited by the amount of circulating tumor DNA and the fraction of cell-free DNA derived from tumor cells in a blood sample.
Joerg Bredno, Jafi Lipson, Oliver Venn, Alexander M Aravanis, Arash Jamshidi   +4 more
doaj   +1 more source

Evaluation of pre-analytical factors affecting plasma DNA analysis. [PDF]

, 2018
Pre-analytical factors can significantly affect circulating cell-free DNA (cfDNA) analysis. However, there are few robust methods to rapidly assess sample quality and the impact of pre-analytical processing. To address this gap and to evaluate effects of
Berens, Michael E, Borad, Mitesh J, Bryce, Alan, Contente-Cuomo, Tania, Dhruv, Harshil D, Farooq, Maria, Gollins, Simon, Liang, Winnie S, LoRusso, Patricia M, Markus, Havell, Murtaza, Muhammed, Ribas, Antoni, Sekulic, Aleksandar, Sivakumar, Shivan, Tran, Nhan L, Trent, Jeffrey M   +15 more
core   +1 more source

A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative [PDF]

, 2016
Recent improvements in next-generation sequencing (NGS) technology have enabled detection of biomarkers in cell-free DNA in blood and may ultimately replace invasive tissue biopsies.
Aberra, Metasebia, Bender, R. Joseph, Brody, Jonathan, Chung, Vincent, Heartwell, Craig, Hendifar, Andrew, Hoos, William A., Madhavan, Subha, Mason, Kimberly, Matrisian, Lynn M., Mikhail, Sam, Petricoin, Emanuel, III, Picozzi, Vincent, Pishvaian, Michael J., Rahib, Lola, Varieur, Katelyn   +15 more
core   +2 more sources

Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis

The International Journal of Biological Markers, 2018
Purpose: Bone metastases from non-small cell lung cancer (NSCLC) are common, and current prognostic stratification methods are challenging to predict outcomes.
Jiguang Jia, Bin Huang, Zhengling Zhuang, Sen Chen   +3 more
doaj   +1 more source

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. [PDF]

, 2017
Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications.
Alva, Ajjai S, Brockman, Scott, Chinnaiyan, Arul M, Chugh, Rashmi, Feng, Felix Y, Grasso, Catherine S, Gursky, Amy, Haakenson, Christine, Henderson, James, Herman, Kirk, Hovelson, Daniel H, Husain, Hatim, Hussain, Maha H, Kamberov, Emmanuel, Kandarpa, Malathi, Kang, Qing, Krauss, John C, Langmore, John, Liu, Chia-Jen, Lonigro, Robert J, Mills, Ryan E, Morgan, Todd M, Quist, Michael J, Ramnath, Nithya, Robinson, Dan, Smith, David C, Talpaz, Moshe, Tesmer, Tim, Tewari, Muneesh, Tomlins, Scott A, Tuck, Missy, Wang, Yugang   +31 more
core   +1 more source

Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA [PDF]

Cancer Discovery, 2014
Abstract The ability to study nonhematologic cancers through noninvasive sampling of blood is one of the most exciting and rapidly advancing fields in cancer diagnostics. This has been driven both by major technologic advances, including the isolation of intact cancer cells and the analysis of cancer cell–derived DNA from blood samples ...
Daniel A, Haber, Victor E, Velculescu
openaire   +2 more sources

Liquid biopsy genotyping in lung cancer: ready for clinical utility? [PDF]

, 2017
Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its ...
Chen, Yi-Lin, Ho, Chung-Liang, Huang, Wei-Lun, Lin, Chien-Chung, Su, Wu-Chou, Wei, Fang, Wong, David T, Yang, Szu-Chun   +7 more
core   +1 more source

Circulating DNA and Survival in Solid Tumors [PDF]

Cancer Epidemiology, Biomarkers & Prevention, 2016
Abstract Background: The ability to undertake molecular analysis to inform on prognosis and predictors of response to therapy is limited by accessibility of tissue. Measurement of total circulating free DNA (cfDNA) or circulating tumor DNA (ctDNA) in peripheral blood may allow easier access to tumor material and help to predict ...
Ocaña, Alberto, Díez-González, Laura, García-Olmo, Dolores C., Templeton, Arnoud J., Vera-Badillo, Francisco, Escribano, María José, Serrano-Heras, Gemma, Corrales-Sánchez, Verónica, Seruga, Bostjan, Andrés-Pretel, Fernando, Pandiella, Atanasio, Amir, Eitan   +11 more
openaire   +3 more sources

Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives [PDF]

, 2019
Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high
Campisi, Giuseppina, Cristaldi, Marta, Di Fede, Olga, Giuliana, Giovanna, Mauceri, Rodolfo, Panzarella, Vera   +5 more
core   +1 more source